In 2018Q4 SEC form is reported Cam Group Holding A’s holdings in Edwards Lifesciences Corp (EW) which was decreased by 50.27%. The company’s stock rose 6.31% with the market as Cam Group Holding A sold 46,450 shares. The institutional investor is holding 45,943 shares, compared to the 92,393 from the previous quarter. And the announced value of the industrial specialties company is $7.04M for the 2018Q4. For a total of 334,120 shares it increased its holding in Johnson & Johnson (NYSE:JNJ) by 33,875 shares in the quarter, and has risen its stake in Cvs Health Corp (NYSE:CVS).

Edwards Lifesciences Corporation (NYSE:EW)’s quarterly earnings will be revealed on April, 23., according to Faxor. Analysts predict $1.23 EPS, which is $0.01 up or 0.82 % from 2018’s $1.22 EPS. If EPS of $1.23 is revealed the profit of EW could hit $255.55 million giving it 36.66 P/E. Last quarter $1.17 EPS was reported. Analysts predicts 5.13 % EPS growth this quarter.

For more Edwards Lifesciences Corporation (NYSE:EW) news published recently go to: Seekingalpha.com, Seekingalpha.com, Seekingalpha.com, Seekingalpha.com or Benzinga.com. The titles are as follows: “Medical Devices Stock Price Gain Opportunity: Edwards Lifesciences – Seeking Alpha” published on March 12, 2019, “Edwards’ Pascal valve cleared in Europe for mitral regurgitation – Seeking Alpha” on February 19, 2019, “Merger Arbitrage Mondays – February 18, 2019 – Seeking Alpha” with a publish date: February 19, 2019, “Edwards Lifesciences: It’s Expensive, But It’s Recession-Proof – Seeking Alpha” and the last “25 Stocks Moving In Tuesday’s Pre-Market Session – Benzinga” with publication date: March 12, 2019.

Edwards Lifesciences Corporation (NYSE:EW) Ratings Coverage

A total of 10 analysts rate Edwards Lifesciences (NYSE:EW) as follows: 5 “Buy”, 3 “Hold” and 2 “Sell”. Тherefore 50% are bullish. (NYSE:EW) has 17 ratings reports on Mar 15, 2019 according to StockzIntelligence. On Wednesday, January 2 the rating was maintained by Citigroup with “Sell”. On Tuesday, March 12 UBS maintained Edwards Lifesciences Corporation (NYSE:EW) rating. UBS has “Neutral” rating and $180 target. On Thursday, October 11 the stock of Edwards Lifesciences Corporation (NYSE:EW) earned “Overweight” rating by Morgan Stanley. On Monday, February 25 Citigroup maintained Edwards Lifesciences Corporation (NYSE:EW) with “Sell” rating. In Friday, December 7 report Morgan Stanley maintained the stock with “Overweight” rating. On Thursday, December 6 the firm has “Outperform” rating by Raymond James given. On Monday, October 29 the rating was maintained by Citigroup with “Sell”. On Friday, January 18 the firm has “Buy” rating given by Bank of America. On Wednesday, February 20 the firm earned “Sell” rating by Barclays Capital. On Tuesday, October 2 the rating was downgraded by Guggenheim to “Neutral”.